Loading...
RGLS logo

Regulus Therapeutics Inc.NasdaqCM:RGLS Stock Report

Market Cap US$617.0m
Share Price
n/a
1Y300.0%
7D-0.6%
1D0.2%
Portfolio Value
​
View

Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$617.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Regulus Therapeutics (RGLS) Stock Overview

A clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. More details

RGLS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 63.23% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year


RGLS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW499,106 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
499,106 investors already sharing narratives
View all narratives

Regulus Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Regulus Therapeutics
Historical stock prices
Current Share PriceUS$8.16
52 Week HighUS$8.35
52 Week LowUS$0.83
Beta0.37
1 Month Change3.42%
3 Month Change444.00%
1 Year Change300.00%
3 Year Change288.57%
5 Year Change14.93%
Change since IPO-98.38%

Recent News & Updates

Recent updates

Analysis Article • Sep 28

Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 12

Regulus surges 15% after Phase 1 data for kidney disease candidate

The shares of clinical-stage biotech Regulus Therapeutics Inc. (NASDAQ:RGLS) climbed ~15% in the pre-market trading Monday after the company announced topline data from its Phase 1 Single-Ascending Dose (SAD) trial for kidney disease candidate RGLS8429. RGLS8429, designed to target Autosomal Dominant Polycystic Kidney Disease (ADPKD), belongs to a drug class known as oligonucleotides. The topline safety and pharmacokinetics data from the study involving healthy volunteers indicated that RGLS8429 was well-tolerated with no serious adverse events, RGLS said. Among 32 patients who received the therapy, there were nine adverse events, out of which only one (sinus infection) was found to be moderate in severity. With the data update from the SAD portion of the study, the company announced the launch of the Phase 1b Multiple Ascending Dose (MAD) study for the candidate, which involves ADPKD patients. The topline data from the first cohort of patients are expected in 1H 2023. Read: Seeking Alpha contributor Bret Jensen takes a deep dive into RGLS with a Hold rating on the stock.
Seeking Alpha • Aug 11

Regulus Therapeutics GAAP loss per share narrows

Regulus Therapeutics press release (NASDAQ:RGLS): Q2 GAAP EPS of -$0.50 (vs. -$0.78 Y/Y). As of Jun. 30, Regulus had $47.5M in cash, cash equivalents and marketable securities.
Analysis Article • Oct 12

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Aug 03

The Read On Regulus Therapeutics

Today, we take an in-depth look at Regulus Therapeutics. This small cap developmental firm is focused on microRNA therapeutics and has multiple 'shots on goal' in its pipeline. A full investment analysis follows in the paragraphs below.
Analysis Article • Jun 09

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Shareholders of Regulus Therapeutics Inc. ( NASDAQ:RGLS ) will have been dismayed by the negative share price return...
Analysis Article • Mar 13

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Unfortunately for shareholders, when Regulus Therapeutics Inc. ( NASDAQ:RGLS ) reported results for the period to...
Analysis Article • Mar 10

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics Inc. ( NASDAQ:RGLS ) shareholders might be concerned after seeing the share price drop 10% in the...

Shareholder Returns

RGLSUS BiotechsUS Market
7D-0.6%2.3%0.8%
1Y300.0%42.3%20.2%

Return vs Industry: RGLS exceeded the US Biotechs industry which returned -13.3% over the past year.

Return vs Market: RGLS exceeded the US Market which returned 10.9% over the past year.

Price Volatility

Is RGLS's price volatile compared to industry and market?
RGLS volatility
RGLS Average Weekly Movement40.4%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: RGLS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RGLS's weekly volatility has increased from 22% to 40% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200734Jay Haganwww.regulusrx.com

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.

Regulus Therapeutics Inc. Fundamentals Summary

How do Regulus Therapeutics's earnings and revenue compare to its market cap?
RGLS fundamental statistics
Market capUS$616.99m
Earnings (TTM)-US$47.52m
Revenue (TTM)n/a
0.0x
P/S Ratio
-13.0x
P/E Ratio

Is RGLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGLS income statement (TTM)
RevenueUS$0
Cost of RevenueUS$36.15m
Gross Profit-US$36.15m
Other ExpensesUS$11.38m
Earnings-US$47.52m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RGLS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/25 05:50
End of Day Share Price 2025/06/24 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regulus Therapeutics Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.
Madhu KumarChardan Capital Markets, LLC